RSS   Newsletter   Contact   Advertise with us
Post Online Media

Intellia Therapeutics appoints Graeme Bell as CFO

Intellia TherapeuticsIntellia Therapeutics, a genome editing company, appointed Graeme Bell as its chief financial officer.

Mr. Bell joins Intellia from his role as Chief Financial Officer at Anacor Pharmaceuticals, Inc., a publicly traded biopharmaceutical company acquired by Pfizer, Inc. in June 2016.

Additionally, Mr. Bell will be responsible for investor relations.

Prior to Anacor, Mr. Bell spent more than 20 years at Merck & Co, Inc., where he held numerous finance and accounting senior-level positions including: CFO of U.S. operations, Controller, Global Pharmaceutical Franchises, CFO United Kingdom subsidiary, and head of investor relations.

He is a Fellow of the Institute of Management Accountants with an MBA from the University of Durham, UK.

Mr. Bell succeeds Sapna Srivastava, Ph.D., who is transitioning to a senior advisory role within Intellia.

Dr. Srivastava has decided to transition from the Chief Financial and Strategy Officer role to a senior advisor primarily due to her personal commitments in New York City.

Dr. Srivastava joined Intellia in April 2015, and played an integral role in helping start up Intellia's financial operations and strategic direction, the Series B private funding, and the initial public offering.

Dr. Srivastava is committed to ensuring a smooth transition of her responsibilities to Mr. Bell. At the conclusion of her advisory role, Dr. Srivastava will transition from Intellia.


 LATEST MOVES FROM Massachusetts 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy